News Sentiment

KPTI sentiment intelligence

Karyopharm Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 61 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 10.34 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+7.7% over one week, +8.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

KPTI5813817 Bond Risk Profile

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 7.7% Price confirming higher
Trend fit Trend active 8.8% over four weeks
Fair value -6.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 42
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 8
Karyopharm 7
PR Newswire 7
simplywall.st 5
Quartr 3
Finviz 3
TradingKey 3

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 21
Analyst action 8
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 61
PR Newswire Direct company coverage

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. announced an inducement grant of 1,200 restricted stock units (RSUs) to a new employee, effective May 31, 2026. This grant was made under Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment. The RSUs will vest over three years, cont

Tone
Positive 61/100
Event
Market update
Published
05 Jun 2026 06:09
Source
PR Newswire
Karyopharm Direct company coverage

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

Karyopharm Therapeutics Inc. announced it will host a virtual fireside chat on June 8, 2026, featuring its senior management and Dr. Robert Coleman, a key opinion leader in endometrial cancer. The webcast, organized by Cantor, will discuss the company's progress and the Phase 3 X

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 22:39
Source
Karyopharm
PR Newswire Direct company coverage

Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

Karyopharm Therapeutics announced it will present results from its Phase 3 SENTRY trial of selinexor plus ruxolitinib in myelofibrosis at ASCO 2026, with simultaneous publication in the Journal of Clinical Oncology. The trial demonstrated a rapid and nearly doubled rate of spleen

Tone
Positive 74/100
Event
Earnings
Published
03 Jun 2026 04:10
Source
PR Newswire